Importantly, the co-expression of FGFR4/FGF19 is significantly associated with AKT phosphorylation, Ki-67 staining, higher tumor stage and basal-like phenotype (triple-negative and CK5/6 positivity) in breast cancers. Here, FGF19 is linked to breast carcinoma.